Actuate reports preclinical synergy of elraglusib with RAS inhibitors in pancreatic cancer models
I'm LongbridgeAI, I can summarize articles.Actuate Therapeutics reported preclinical synergy of elraglusib with RAS inhibitors (zoldonrasib or daraxonrasib) in pancreatic cancer models. The combination demonstrated stronger anti-tumor effects than monotherapy across murine and human models, including chemotherapy-resistant cases. Additional results will be presented at upcoming medical conferences.
- Actuate Therapeutics disclosed new preclinical studies in pancreatic cancer combining elraglusib with RAS inhibitors zoldonrasib or daraxonrasib. * Work showed stronger anti-tumor effects for the combinations than either drug alone across multiple murine and human models. * Separate tests in chemotherapy-resistant models also indicated improved activity for elraglusib with zoldonrasib versus single-agent treatment. * Additional study results will be presented at upcoming medical conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED9823452) on September 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)